Explore All 3116 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 10, 2003 |
| Target | SangStat Medical |
| Sector | Life Science |
| Buyer(s) | Genzyme |
| Deal Type | Add-on Acquisition |
| Deal Value | 600M USD |
| Advisor(s) | BofA Securities (Financial) Skadden, Arps, Slate, Meagher & Flom (Legal) |
FILTER BY
Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.
| Deal Context for Buyer | # |
|---|---|
| Overall | 6 of 12 |
| Sector: Life Science | 4 of 9 |
| Type: Add-on Acquisition | 5 of 10 |
| State: California | 1 of 1 |
| Country: United States | 6 of 9 |
| Year: 2003 | 1 of 1 |
| Size (of disclosed) | 4 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2001-09-27 |
Novazyme Pharmaceuticals
Oklahoma City, Oklahoma, United States Novazyme is a development stage biotechnology company focused on drugs to treat lysosomal storage diseases |
Buy | $137M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-12-21 |
ILEX Oncology
San Antonio, Texas, United States ILEX Oncology, Inc. is a drug development company focused exclusively on the accelerated development of drugs for the treatment and prevention of cancer. ILEX Oncology was founded in 1992 and is based in San Antonio, Texas. |
Buy | $1.0B |
